Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark

Abstract

Background: To estimate the health economic consequences of the recently introduced PPSV23 vaccination programme for persons aged 65+ in Denmark and of a potential extension of the programme to include persons aged 60-64 years. Research design and methods: A Markov model was adapted to the Danish healthcare setting to simulate the epidemiological and economic burden of invasive pneumococcal disease and nonbacteremic pneumococcal pneumonia using information from published sources and Danish databases. Results: We found that the recent introduction of an age-based vaccination programme offering PPSV23 vaccination to the population of persons aged 65+ in Denmark will lead to a societal gain of EUR 72.0 million and prevent 19,707 cases of pneumococcal disease and 1,308 deaths per 1 million persons during the five-year study period.Similarly, we estimate that extending the programme to include persons aged 60-64 will lead to a gain of EUR 14.6 million per 1 million persons and prevent an additional 6,223 cases of pneumococcal disease and 185 deaths. Conclusion:The recent introduction of the age-based vaccination programme offering PPSV23 vaccination to all persons aged 65+ in Denmark is cost-effective. This is also the case if the programme is extended to include persons aged 60-64.

Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature

“… Country Author (Ref.) Analysis type Intervention Comparator Assessment Austria Walter et al 110 BIM PCV13 or PPV23 None Positive Belgium Marbaix et al 71 CUA PCV13 None Positive Belgium Willem et al 112 CUA PPV23 PCV13+PPV23 Positive Denmark Sevilla et al 95 CA PCV13 NR Positive Denmark Birck et al 41 CEA PPV23 None Positive EU* Esposito et al 52 CA NR NR Positive Finland THL 103 CEA NR NR NR France HCSP 59 CUA PCV13+PPV23 PPV23 Positive Germany Kuchenbecker et al 67 <...…”

“…There were four records estimating serotype coverage rates for specific vaccines, with one study each providing estimates for Denmark 41 Poland, 75 Greece, 70 and Croatia. 43 Across the timeframes for the different estimates, there was more variation in the serotype coverage of PCV13 than PPV23.…”

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult

“…The study showed that PCV13 was more cost-effective than PPSV23 ( 12 ). Meanwhile, the study conducted in Denmark suggested that implementing a PPSV23 vaccination program for all older adult aged ≥ 65 years is cost-effective ( 13 ). Even though there are many economic studies on the older adult from various countries, the generalizability of the results should be considered due to each country’s diverse backgrounds such as pneumococcal serotype distributions and vaccine support from non-profit organization.…”